Drug Trial Radar · NCT05501418
Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With COVID-19
Last checked: Nov 20, 2026Latest source record: Sep 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
75
Planned (sponsor's estimate)
Start
Aug 5, 2020
Primary completion
Dec 31, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Ever Supreme Bio Technology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 15, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 20 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is to explore the safety and efficacy of using UCMSC01 in patients with COVID-19 infection via IV stem cell administration. The novelty of the current UMSC01 treatment is the single IV infusion of UMSC01 to the worldwide emergency outbreaks of COVID-19. We hypothesize that sufficient UMSC01 retention in lung may modulate the systemic inflammatory responses.
Conditions
- COVID-19 Infection
Interventions
Allogeneic umbilical cord mesenchymal stem cellsBiological
UMSC01 cells will be IV infusion with 12 months of follow up after treatment.
Controlled normal salineBiological
Normal saline will be IV infusion with 12 months of follow up after treatment.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Two Co-Primary Efficacy EndpointsTime frame: 21 days of the treatment period
- Two Co-Primary Efficacy EndpointsTime frame: 21 days of the treatment period
Locations
1 site in 1 country. Site status is shown where the registry gives one.
China Medical University Hospital
Taichung, Non-US, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.